Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01983462 · ClinicalTrials.gov registry record · Phase 2
Vascular Dysfunction in Human Obesity Hypertension
A Phase 2 study, sponsored by Gary L. Pierce.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT01983462: Clinical Trial Phase 2 study, sponsored by Gary L. Pierce.
NCT01983462 is a Phase 2 study that was terminated before completion, run by Gary L. Pierce. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01983462, a Phase 2 study, was terminated before completion, sponsored by Gary L. Pierce.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of the study is to test the effects of blocking sympathetic nerve activity with a drug called clonidine on blood vessel function and muscle nerve activity in adults who are obese and have high blood pressure. The cohort of subjects will consist of 69 healthy young men and women age 18-79 years who are obese, defined as a body mass index \> or = to 30 kg/m2, who have untreated systolic hypertension (systolic blood pressure \> or = to 130 - \<180 mmHg- average of at least 3 measurements 2 min apart after 10 min seated resting position). These 69 subjects will then be randomized to 3 treatment arms: clonidine (0.1 mg/day), hydrochlorothiazide (25 mg/day) or placebo for 4 weeks in years 1 and 2. All tablets will be encapsulated by to look identical. Subjects will randomly (1:1:1) receive one of the following combinations in a double-blind, placebo-controlled design: 1. Oral clonidine (0.1 mg twice/day) 2. Oral hydrochlorothiazide (12.5 mg twice/day) 3. Oral placebo I
Primary Outcome
Carotid-femoral pulse wave velocity (PWV)
Interventions
- DRUG Placebo
- DRUG Clonidine
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-10 |
| Est. Completion | 2020-06 |
| Phase | Phase 2 |
Why NCT01983462 stopped before completion
NCT01983462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01983462 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01983462 about?
NCT01983462 is a clinical study titled "Vascular Dysfunction in Human Obesity Hypertension". The purpose of the study is to test the effects of blocking sympathetic nerve activity with a drug called clonidine on blood vessel function and muscle nerve activity in adults who are obese and have high blood pressure. The cohort of subjects will consist of 69 healthy young men and women age 18-7...
What is the current status of trial NCT01983462?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2013-10. Estimated completion is 2020-06.
What interventions are being tested in trial NCT01983462?
The interventions under investigation include: Placebo (DRUG), Clonidine (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT01983462?
This trial is sponsored by Gary L. Pierce, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01983462's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia